the benefits of glp-1 drugs beyond obesity Poll: 1 in 8 Adults

54,55 Cardiovascular outcomes The EMPA-REG OUTCOME study by Zinman et al was designed specifically to evaluate the effect of empagliflozin in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD)

There is also evidence that SCFAs decline the release of TNF- from neutrophils (Lee et al., 2019), which is also one of the typical pro-inflammatory cytokines that trigger subclinical inflammation

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

8.1 (e.g., inhaled insulin, a-glucosidase inhibitors, colesevelam, bromocriptine, and pramlintide) may be tried in specific situations but are not often used due to modest efficacy in type 2 diabetes, the frequency of administration, the potential for drug interactions, and/or side effects

To learn more about Farxiga, see these articles: All About Farxigas Dosage Farxiga and Cost: What You Need to Know Farxiga vs

doi: 10.3748/WJG.V30.I23.2964 60 MacDonaldPEEl-kholyWRiedelMJSalapatekAMFLightPEWheelerMB